Inventor

NIELSEN ELSEBET OSTERGAARD

DK22 patents

⚠️ This page may combine multiple inventors who share the name “NIELSEN ELSEBET OSTERGAARD”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

NIELSEN ELSEBET OSTERGAARD

NEUROSEARCH AS

8-Azabicyclo(3,2,1)oct-2 ene and octane derivatives as cholinergic ligands at nicotinic ACh receptors

Heteroaryl diazabicycloalkanes, their preparation and use

8-azabicyclo[3.2.1]oct-2-ene and -octane derivatives

8-azabicyclo(3,2,1)oct-2-ene and octane derivatives as cholinergic ligands at nicotinic ACh receptors

9-azobicyclo[3.3.1] non-2-ene derivatives as cholinergic ligands at nicotinic ACH receptors

Azabicyclo derivatives and their use

Compounds, their preparation and use

Heteroaryl-diazabicycloalkanes

Heteroaryl diazacycloalkanes, their preparation and use

Heteroaryl diazacycloalkanes, their preparation and use

8-Azabicyclo[3.2.1]oct-2-ene and -octane derivatives technical field

3,8-substituted 8-aza-bicyclo[3.2.1]octane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors

1,4-diaza-bicyclo[3.2.2]nonyl heteroaryl derivatives useful as nicotinic acetylcholine receptor ligands

Disubstituted morpholine, oxazepine or thiazepine derivatives, their preparation and their use as dopamine d4 receptor antagonists

1,4-diaza-bicyclo[3.2.2]nonyl pyrimidine derivatives and their medical use

3-aza-spiro[5.5]undecane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors

3,9-diaza-spiro[5.5]undecane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors

3, 9-diazabicyclo(3.3.1)non-3-yl-aryl methanone derivatives as nicotinic acetylcholine receptor agonists

2,5-diazabicyclo[2.2.1]heptane derivatives

PETERS DAN

Chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors

8-aza-bicyclo[3.2.1]octane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors

ANIONA APS

Chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors